As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...
Scientists at Auburn University have made an important discovery that could improve cancer treatments. Just like a coach ...
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...
Immutep (IMMP) announces positive data from investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA ... of anti-PD-1 and doublet chemotherapy ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
First Immutep reported on positive data from the Phase I trial evaluating its eftilagimod alpha (efti) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback